

Folate Receptor alpha



Lung Adenocarcinoma stained with FRalpha [26B3.F2] from left to right: 1+ staining, 2+ staining, 3+ staining

Mouse anti-human Folate Receptor alpha monoclonal antibody [26B3.F2] specifically recognizes the alpha isoform of Folate Receptor. FRalpha is a cell surface protein that is primarily expressed on the apical surface of some polarized epithelial cells of normal tissues (such as kidney, lung, breast, and salivary glands) and on several cancers of epithelial origin, including ovarian cancer, thyroid cancer, non-small cell lung adenocarcinoma (NSCLC) and endometrial cancers.

This *in vitro* diagnostic IHC kit is designed to detect FRalpha expression in formalin fixed paraffin embedded (FFPE) tissues.

- ▶ High Level of FRa in detected in lung adenocarcinoma ¹
- ▶ Often over-expressed in ovarian serous adenocarcinoma ^{2,3}
- ▶ Identify subpopulations of patients that express FRalpha

Ordering Information	Cat. No.
Folate Receptor alpha IHC Assay Kit	BRI 4006K AA
Folate Receptor alpha IHC Assay Kit (intelliPATH)	IPI 4006K G10

References

1. Nunez, MI, *et. al.* High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation. *J. Thoracic Oncol*:2012(7)833-840
2. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. *Gynecol Oncol.* 2008 Mar;108(3):619-26.
3. Shen DH, Xie JL, Zhang YL, Wang Y. Expression of folate receptor alpha in ovarian epithelial tumors. *Zhonghua Bing Li Xue Za Zhi.* 2010 Nov;39(11):747-51.
4. Brown Jones M, Neuper C, Clayton A, Mariani A, Konecny G, Thomas MB, Keeney G, Hartmann L, Podratz KC. Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas. *Int J Cancer.* 2008 Oct 1;123(7):1699-703.
5. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. *Curr Opin Chem Biol.* 2009 Jun;13(3):256-62.
6. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. *Cancer Metastasis Rev.* 2008 Dec;27(4):655-64.
7. Zhao X, Li H, Lee RJ. Targeted drug delivery via folate receptors. *Expert Opin Drug Deliv.* 2008 Mar;5(3):309-19.
8. Lu Y, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. *Adv Drug Deliv Rev.* 2004 Apr 29;56(8):1161-76.
9. Armstrong DK, Bicher A, Coleman RL, Gibbon DG, Glenn D, Old L, Senzer NN, Schneeweiss A, Verheijen RH, White AJ, Weil S. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse. *J Clin Oncol.* 2008 May 20;26(15S): 5500
10. Salazar M, Ratnam M. The folate receptor: What does it promise in tissue-targeted therapeutics? *Cancer Metast Rev.* 26(1):141-52.
11. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. *Cancer Immunity.* 2007 Mar 9;7:6